Novel Quinazoline Derivatives Inhibit Splicing of Fungal Group II Introns

Area of Science:

• Molecular Biology
• Medicinal Chemistry
• Antimicrobial Drug Discovery

Background:

• Self-splicing group II introns are essential genetic elements in various organisms.
• Targeting RNA structures offers a novel therapeutic strategy against microbial pathogens.
• Candida parapsilosis poses a significant threat due to its prevalence and resistance patterns.

Purpose of the Study:

• To identify small molecules that inhibit the function of self-splicing group II introns.
• To develop potent antifungal agents targeting RNA tertiary structures.
• To explore the therapeutic potential of RNA-targeting compounds against Candida parapsilosis.

Main Methods:

• High-throughput screening of small molecules against a yeast group II intron.
• Synthetic optimization of identified inhibitor scaffolds.
• Antifungal activity assays against Candida parapsilosis and other yeasts.
• Gene-specific activity profiling of optimized compounds.

Main Results:

• Discovery of a novel class of small molecule inhibitors targeting yeast group II introns.
• Synthetic optimization led to compounds with enhanced inhibitory and antifungal activity.
• Highly refined compounds demonstrated potent, gene-specific antifungal efficacy against Candida parapsilosis.
• Successful validation of RNA tertiary structure as a druggable target.

Conclusions:

• Small molecules targeting RNA tertiary structures of group II introns can exhibit significant antifungal activity.
• This study validates a combined RNA screening and medicinal chemistry approach for identifying novel antimicrobial agents.
• The identified compounds represent promising leads for the development of new antifungal therapies, particularly against Candida parapsilosis.